title: Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
authors.affiliation: Lymphoma/Myeloma Section, Roswell Park Cancer institute, Elm and Carton Streets, Buffalo, NY 14263, USA. myron.czuczman@roswellpark.org
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D017410:Practice Guidelines as Topic; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016499:Radioimmunotherapy; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone